Company profile for SparingVision

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and a...
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects 40,000 people in France and nearly 2 million worldwide.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
55, Rue de Lyon Paris, Ile-de-France 75012
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/28/3175310/0/en/SparingVision-Doses-First-Patient-with-SPVN20-for-Advanced-Retinitis-Pigmentosa-in-NYRVANA-Trial.html

GLOBENEWSWIRE
28 Oct 2025

https://www.globenewswire.com//news-release/2024/01/24/2815094/0/en/SparingVision-Reaches-Final-Dose-Escalation-Step-in-PRODYGY-Trial-with-SPVN06-for-retinitis-pigmentosa.html

GLOBENEWSWIRE
24 Jan 2024

https://www.globenewswire.com//news-release/2023/08/30/2734166/0/en/SparingVision-Reports-Positive-Initial-Safety-Data-from-the-first-cohort-treated-in-its-PRODYGY-Phase-I-II-Gene-Therapy-Trial.html

GLOBENEWSWIRE
30 Aug 2023

https://www.globenewswire.com/news-release/2023/07/12/2703375/0/en/SparingVision-sells-ex-vivo-GIRK-technology-to-Tenpoint-Therapeutics.html

GLOBENEWSWIRE
12 Jul 2023

https://www.globenewswire.com/news-release/2023/04/05/2641518/0/en/SparingVision-appoints-Joseph-C-Papa-as-Chairman.html

GLOBENEWSWIRE
05 Apr 2023

https://www.globenewswire.com//news-release/2022/12/01/2565749/0/en/SparingVision-s-lead-asset-SPVN06-clears-IND-application-in-the-US-for-the-treatment-of-retinitis-pigmentosa.html

GLOBENEWSWIRE
01 Dec 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty